Actively leading a team to conduct post-market surveillance by monitoring the safety and effectiveness of therapies for regulatory compliance, helping identify unmet needs, and comparing the effectiveness of treatments for Multiple Myeloma based on Registry, EHR & Claims databasesHealth Economics and Outcomes Research AnalysisCollaborated with the domain experts of a leading US-based bio- pharmaceutical company for high-impact HEOR studies to generate Real-world EvidenceConducted studies to determine potential burden of illness by analyzing direct cost and healthcare resource utilization, support drug pricing, regulatory compliance, highlight unmet medical needs, compare effectiveness of treatments based on EHR and ClaimsRWDConducted analysis such as Overall Survival (OS), Progression Free Survival (PFS-Both EMA and FDA rules), COX Proportional Hazard models, treatment Patterns.Patients Quality of Life(QoL) analysis.Line of Therapy GenerationGenerated Line of therapy for Multiple Myeloma patients in PREAMBLE/MDV/FI database.Analyzed data from clinical trials and collaborated with medical professionals to develop comprehensive line of therapy for the pharma database.Reduced research time by 30% by implementing new line of therapyImproved patient outcomes by providing more efficient and accurate treatment options